Logo (Logo1)
Pemetrexed Injection, Solution, Concentrate
Product Images NDC 0409-0004
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 0409-0004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Logo (Logo)
Chemical Structure (Pemetrexed 01)
Chemical structure of Pemetrexed, shown as a detailed molecular diagram including atoms and bonds, with a notation indicating 2.5 molecules of water of hydration (2.5H2O).*
Figure 1 (Pemetrexed 02)
A Kaplan-Meier survival curve graph comparing two treatment groups over a 30-month period. The solid line represents patients treated with Pemetrexed plus Cisplatin (PC), and the dotted line represents those treated with Gemcitabine plus Cisplatin (GC). The y-axis shows survival probability from 0.0 to 1.0, and the x-axis shows survival time in months from 0 to 30. Below the x-axis, the number of patients at risk for each group is tabulated at various time points.*
Figure 2 (Pemetrexed 03)
A survival probability graph comparing two treatment groups: Pemetrexed + Cisplatin (solid line) and Gemcitabine + Cisplatin (dotted line). The x-axis represents survival time in months (0 to 30), while the y-axis shows survival probability (0 to 1). The number of patients at risk is listed below the x-axis for each treatment group at various time points.*
Figure 3 (Pemetrexed 04)
A Kaplan-Meier survival curve comparing survival probability over time in months for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes a table listing the number of patients at risk at various time points for each group.*
Figure 4 (Pemetrexed 05)
A Kaplan-Meier survival curve comparing survival probability over time (up to 42 months) between patients treated with Pemetrexed and those given a placebo. The graph shows higher survival probability for the Pemetrexed group. Below the graph, a patient risk table lists the number of patients remaining at risk at various monthly intervals for both groups.*
Figure 5 (Pemetrexed 06)
A survival probability Kaplan-Meier curve showing survival over time in months for two groups: patients treated with Pemetrexed and those given placebo. The graph plots survival probability on the y-axis against survival time in months on the x-axis, with Pemetrexed patients consistently showing higher survival probability than placebo patients. A table below lists the number of patients at risk at various time points for each group.*
Figure 6 (Pemetrexed 07)
A survival probability Kaplan-Meier curve comparing Pemetrexed and placebo over a 42-month period. The x-axis shows survival time in months, and the y-axis shows survival probability. A table below lists the number of patients at risk for each group at various time intervals.*
Figure 7 (Pemetrexed 08)
A line graph showing survival probability over time (in months) comparing patients treated with Pemetrexed versus placebo. The solid line represents Pemetrexed and the dotted line represents placebo. Below the graph, a table lists the number of patients at risk at different time points for each group.*
Figure 8 (Pemetrexed 09)
A Kaplan-Meier survival curve comparing survival probability over time (months) between two groups: Pemetrexed plus Cisplatin (solid line) and Cisplatin alone (dotted line). The x-axis shows survival time in months, and the y-axis shows survival probability. Below the graph is a table listing the number of patients at risk at various time points for each treatment group.*
Principal Display Panel (4 mL Vial Label)
Pemetrexed Injection 100 mg/4 mL (25 mg/mL) vial label. It is a sterile single-dose vial for intravenous infusion after dilution. The label includes storage instructions to keep refrigerated at 2°C to 8°C (36°F to 46°F) and a warning that it is a hazardous drug. Distributed by Hospira, Inc., Lake Forest, IL, USA. The label also features a barcode and lot/expiration date fields.*
Principal Display Panel (4 mL Vial Carton)
Pemetrexed Injection 100 mg/4 mL (25 mg/mL) concentrate in a single-dose vial for intravenous infusion after dilution. The label indicates 1 x 4 mL vial, NDC 0409-0020-02, manufactured by Zydus Hospira Oncology Pvt. Ltd. and distributed by Hospira, Inc. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F). The label includes warnings for hazardous drug handling.*
Principal Display Panel (20 mL Vial Label)
Label for Pemetrexed Injection 500 mg/20 mL (25 mg/mL) concentrate for intravenous infusion. The label states it is a sterile, single-dose vial requiring refrigerated storage at 2°C to 8°C (36°F to 46°F). It includes a warning for hazardous drug handling and mentions dilution before infusion. Manufactured by Hospira, Inc., the label also features a barcode and lot/expiration placeholders.*
Principal Display Panel (20 mL Vial Carton)
Packaging label for Pemetrexed Injection 500 mg/20 mL (25 mg/mL) concentrate for intravenous infusion by Hospira, Inc. The label indicates a single-dose vial with storage instructions at 2°C to 8°C (36°F to 46°F), dilution directions, and warnings of hazardous drug handling. Manufactured by Zydus Hospira Oncology Pvt. Ltd., India, and distributed by Hospira, Inc., Lake Forest, IL, USA.*
Principal Display Panel (40 mL Vial Label)
Label for Pemetrexed Injection 1 g/40 mL (25 mg/mL) concentrate for intravenous infusion, distributed by Hospira, Inc. The label includes storage instructions (2°C to 8°C), a warning for hazardous drug status, and dilution directions to 100 mL with 0.9% Sodium Chloride Injection. The label also shows a barcode and batch information areas for lot and expiration dates.*
Principal Display Panel (40 mL Vial Carton)
Packaging label for Pemetrexed Injection 1 g/40 mL (25 mg/mL) concentrate for intravenous infusion. The label states it is a single-dose vial with a portion to discard if unused. It includes dilution instructions, storage conditions (refrigerate at 2°C to 8°C), and manufacturer details (Zydus Hospira Oncology Private Ltd. and Hospira, Inc.). Warnings for hazardous drug are prominently displayed.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
